Gene mutations help leukemia drug fight squamous cell lung cancer
April 4th, 2011 - 5:28 pm ICT by ANIWashington, Apr 4 (ANI): Researchers have identified a mutation in a gene called DDR2 that may indicate which patients with squamous cell lung cancer will respond to a leukemia drug called dasatinib.
According to lead researcher Matthew Meyerson, professor of pathology at the Dana Farber Cancer Institute, there are currently no targeted therapies for squamous cell lung cancer.
Using standard genetic sequencing techniques, Meyerson and colleagues identified mutations in the DDR2 kinase gene in about 3 percent of squamous cell lung cancers and cell lines.
Furthermore, they found that tumor cells with these DDR2 mutations responded to treatment with dasatinib.
A patient whose cancer carried a DDR2 mutation also showed a clinical response to dasatinib.
“Dasatinib is an existing therapy for chronic myelogenous leukemia with a long history and a strong safety profile,” said Meyerson.
“The results of this study clearly encourage a clinical trial to test dasatinib in the setting of squamous cell lung cancer,” he added.
The findings are published in Cancer Discovery. (ANI)
- Molecular signature may tell which cancer patients will respond to therapy - Sep 07, 2009
- 'Smart' lung cancer drug shows promise - Oct 28, 2010
- New genetic signatures of breast cancer drug resistance identified - Jan 11, 2011
- Targeted drug therapy shows promise against deadly form of lung cancer - Nov 02, 2010
- Mouse genome offers human cancer clue - Mar 24, 2011
- New study shows evidence of stem cells' pivotal role in cancer - Dec 22, 2010
- New drug shows promise against platinum resistant ovarian cancer - Oct 10, 2010
- Small molecule may deactivate enemy of cancer-fighting p53 - Dec 08, 2010
- Scientists stumble upon 'stop cancer' gene - Nov 16, 2011
- How melanoma tumours evade drug treatment - Nov 25, 2010
- Personalized cancer medicine now a step closer to reality - Apr 16, 2011
- Smoking and radiation therapy for head, neck cancers don't mix - Nov 17, 2010
- Genetic change helps lung tumors spread to other parts of the body - Apr 07, 2011
- Scientists decode DNA of lung cancer genes - Oct 23, 2008
- Cheap, fast test identifies aggressive type of lung cancer in never-smokers - Feb 26, 2011
Tags: cell lung cancer, chronic myelogenous leukemia, clinical response, clinical trial, dana farber cancer, dana farber cancer institute, dasatinib, ddr2, drug fight, farber cancer institute, gene mutations, leukemia, leukemia drug, lung cancer, lung cancers, meyerson, mutation, safety profile, strong safety, tumor cells